Navigation Links
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
Date:3/30/2011

SHELTON, Conn., March 30, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the appointment of James B. Jones, M.D., Pharm.D., to the position of Chief Medical Officer.  In this role, Dr. Jones will oversee the ongoing clinical development of Cara's lead drug candidate, CR845, a novel, peripherally-restricted kappa opioid agonist, which is currently in Phase 2 development for treatment of post-operative pain.

"We are delighted to add someone of Jim's clinical background and drug development experience to the Cara team," said Derek Chalmers, President and CEO of Cara Therapeutics.  "We look forward to benefiting from his considerable success in developing novel analgesics as we continue the clinical development of CR845."

Dr. Jones most recently was the Chief Medical Officer at Strativa Pharmaceuticals, a division of Par Pharmaceuticals, Inc. Previously, he was the VP of Clinical Development and Medical Affairs at Xanodyne Pharmaceuticals where he was instrumental in the approval and subsequent launch of Zipsor™ (diclofenac potassium).  Prior to Xanodyne, Dr. Jones was VP of Clinical Development at Alpharma Pharmaceuticals where he was actively involved in the development of EMBEDA™ (morphine sulfate and naltrexone hydrochloride). Other analgesics/CNS compounds that Dr. Jones has worked on include Lusedra (fospropofol disodium) while at Guilford Pharmaceuticals as well as valdecoxib and parecoxib while at Pharmacia. Dr. Jones received his Doctorate of Medicine degree from the University of Pennsylvania and his Doctorate of Pharmacy from Purdue University.

"I am very enthusiastic to join Cara and to be involved in the clinical development of CR845," said Dr. Jones.  "I believe that CR845 has the potential to fill an important unmet medical need in the pain field and could serve as a new first-in-class and best-in-class peripherally acting kappa opioid agonist for the treatment of both acute post-op pain and chronic pain conditions."

About CR845

CR845 is a highly selective, peripherally restricted kappa opioid receptor agonist currently in Phase 2 clinical development for the treatment of post-operative pain.  A randomized, placebo-controlled Phase 2 study has provided evidence of analgesic efficacy of CR845 administered as a single intravenous dose to women following laparoscopic hysterectomy.  In this study, in addition to decreases in reported pain levels, patients receiving CR845 required substantially lower amounts of post-operative opioids and showed a significant reduction in the incidence of post-operative nausea. Cara recently completed a Phase 1b repeat dose safety study of intravenous CR845 and plans to initiate additional Phase 2 efficacy studies of the drug in 2011. In addition, the Company plans to initiate a phase 1 safety and pharmacokinetic study of an oral capsule formulation of CR845 shortly. More than 140 human subjects have been exposed to CR845 to date.  The safety profile of the drug has been excellent with no cases of dysphoric reactions or hallucinations as seen previously with centrally-acting kappa opioids.  

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. In addition to CR845, Cara's current pipeline includes near-term clinical development candidates within multiple proprietary classes of peripherally restricted cannabinoids with preclinical analgesic and anti-inflammatory activity. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen™ technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies, and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
2. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
3. Osseon™ Therapeutics Introduces Osseoflex® BT Steerable Bone Tamp
4. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
5. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
6. Reportlinker Adds Therapeutics for Immune System Disorders
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
9. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
10. Echo Therapeutics Announces 2010 Financial Results
11. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):